Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

November 13, 2024

Study Completion Date

December 31, 2025

Conditions

Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

Interventions

DRUG

Avelumab

Given IV

DRUG

Berzosertib

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER